Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2022-03-30 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
独立董事2021年度述职报告（刘光福）
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of Anhui Anke Biotechnology (Group) Co., Ltd. for the year 2021. It covers the director's attendance at board and shareholder meetings, independent opinions on various company matters including appointments, related party transactions, audit firm reappointment, internal control evaluations, and protection of investor rights. The content is focused on the independent director's duties and oversight activities during the fiscal year 2021. This type of document is a formal report on the independent director's work and opinions, which is typically part of governance and management reporting rather than a full annual report or audit report. It is not a brief announcement or a certification letter but a substantive report on board/management activities and oversight. Therefore, the most appropriate classification is Board/Management Information (MANG).
2022-03-30 Chinese
公司章程（2022年3月）
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association for 安徽安科生物工程（集团）股份有限公司, dated March 2022. It includes comprehensive provisions on company governance, shareholder rights, board structure, share issuance, share transfer, shareholder meetings, voting procedures, and other corporate governance matters. It references laws such as the Company Law and Securities Law of China and covers internal rules and procedures for the company and its shareholders. There is no indication that this is an annual report, financial report, earnings release, or any other type of financial filing. Instead, it is a governance document outlining the company's internal rules and governance practices. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and content confirm it is a full governance report, not a brief announcement or notice.
2022-03-30 Chinese
2021年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2021 Annual Report Summary" of 安徽安科生物工程(集团)股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2021, including revenue, net profit, assets, and shareholder information. It also discusses business operations, industry conditions, and company strategy for the year. The length is substantial (15,000 characters), and it includes comprehensive financial and operational information typical of an annual report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-03-30 Chinese
国元证券关于安科生物使用闲置自有资金和闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from Guoyuan Securities regarding the use of idle self-owned funds and idle raised funds by Anhui Anke Biotechnology (Group) Co., Ltd. for cash management. It includes regulatory references, approval procedures, risk assessments, and opinions from independent directors and the supervisory board. The document is a formal verification and opinion letter from the sponsor institution, not a financial report or announcement of voting results. It does not contain financial statements or earnings data, nor is it a proxy or AGM material. It is a regulatory compliance and verification document related to the use of funds, fitting best under Regulatory Filings (RNS). The document length is under 5,000 characters, but it is not merely an announcement of a report publication; it is a substantive verification opinion. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2022-03-30 Chinese
关于2021年度日常关联交易确认和2022年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the confirmation of daily related party transactions for the fiscal year 2021 and the forecast for 2022. It includes detailed descriptions of related party transactions, pricing principles, related parties' background, independent directors' opinions, and verification opinions from the sponsor institution. The document is a regulatory announcement about related party transactions, which is a common disclosure for listed companies in China. It does not contain financial statements or comprehensive financial performance data, nor is it a report like an annual or interim report. It is not a voting result, management change, or earnings release. It is a regulatory filing disclosing related party transactions as required by stock exchange rules. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (6595 characters) and content confirm it is a full announcement, not a brief notice or report publication announcement.
2022-03-30 Chinese
关于募集资金年度存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金年度存放与使用情况专项报告" which translates to "Annual Report on the Storage and Use of Raised Funds." It details the amount of funds raised, their usage, balances, and compliance with regulatory requirements for the year 2021. It references regulatory guidelines from the Shenzhen Stock Exchange and the China Securities Regulatory Commission, and includes detailed financial figures about fundraising and usage. The document is about the annual usage and management of capital raised by the company, which fits the category of Capital/Financing Update (CAP). The document length is 4742 characters, which is sufficient to contain substantive financial data and analysis, not just an announcement. Therefore, it is not a report publication announcement or a regulatory filing. It is not an annual report or interim report, but a specialized report on fundraising capital usage. Hence, the best fitting category is Capital/Financing Update (CAP).
2022-03-30 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.